97. Ulcerative colitis
2,269 clinical trials,   1,331 drugs   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-000045-59-GB
(EUCTR)
17/03/200915/07/2008Multicentre, controlled, randomized, investigator-blinded, comparative study of oral mesalazine 4g per day once daily versus 4g per day in two divided doses in patients with active ulcerative colitis. - MOTUSMulticentre, controlled, randomized, investigator-blinded, comparative study of oral mesalazine 4g per day once daily versus 4g per day in two divided doses in patients with active ulcerative colitis. - MOTUS Patients with mild to moderate active ulcerative colitis
MedDRA version: 9.1;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode
Product Name: Pentasa 2g sachet prolonged release granules (95%)
INN or Proposed INN: MESALAZINE
Ferring Pharmaceuticals Ltd.NULLNot RecruitingFemale: yes
Male: yes
398United Kingdom;Netherlands;Belgium;France
2EUCTR2008-000045-59-BE
(EUCTR)
23/12/200822/09/2008Multicentre, controlled, randomized, investigator-blinded, comparitive study of oral Mesalazine 4 g per day Once daily versus 4 g per day in Two divided doses in patients with Active Ulcerative Colitis. - MOTUSMulticentre, controlled, randomized, investigator-blinded, comparitive study of oral Mesalazine 4 g per day Once daily versus 4 g per day in Two divided doses in patients with Active Ulcerative Colitis. - MOTUS Patients with mild to moderate ulcerative colitisProduct Name: Pentasa 2g sachet prolonged release granules (95%)
INN or Proposed INN: MESALAZINE
Ferring SASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
398United Kingdom;Netherlands;Belgium;France
3EUCTR2008-000045-59-NL
(EUCTR)
06/10/200813/08/2008Multicentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative colitiS - MOTUSMulticentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative colitiS - MOTUS Patients with mild to moderate ulcerative colitis
MedDRA version: 9.1;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode
Product Name: Pentasa 2g sachet prolonged release granules (95%)
INN or Proposed INN: MESALAZINE
Ferring SASNULLNot RecruitingFemale: yes
Male: yes
398United Kingdom;Netherlands;Belgium;France
4EUCTR2008-000045-59-FR
(EUCTR)
04/06/200822/04/2008Multicentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative colitiS - MOTUSMulticentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative colitiS - MOTUS Patients with mild to moderate ulcerative colitis
MedDRA version: 9.1;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode
Product Name: Pentasa 2g sachet prolonged release granules (95%)
INN or Proposed INN: MESALAZINE
Ferring SASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
398United Kingdom;Netherlands;Belgium;France